GlassScriptPhysician profile
Donald D Suh
NPI 1558364190
$2,099.32
in general payments reported to CMS, 2019-2025
32 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $247 · 2021: $65.86 · 2022: $257 · 2023: $311 · 2024: $244 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $350.50 | 2019-2025 | Xtandi, Myrbetriq |
| Abbvie INC. | $333.44 | 2019-2025 | Lupron Depot, Botox |
| Boston Scientific Corporation | $159.18 | 2019-2020 | |
| Pfizer INC. | $141.72 | 2019-2024 | |
| Janssen Biotech, INC. | $134.78 | 2019-2024 | Erleada |
| Neotract INC. | $125.23 | 2019-2020 | |
| Teleflex LLC | $99.82 | 2022-2024 | Urolift |
| Coloplast Corp | $64.04 | 2019-2020 | |
| Amgen INC. | $56.11 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $55.70 | 2019 | |
| Urogen Pharma, INC. | $49.58 | 2024 | |
| Baxter Healthcare | $40.86 | 2019-2020 | |
| Urovant Sciences INC | $37.83 | 2022 | |
| Bioprotect Medical, INC. | $37.45 | 2025 | Bioprotect Balloon Implant System |
| Verity Pharmaceuticals INC. | $37.40 | 2022-2025 | Trelstar |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $35.83 | 2019 | |
| Allergan, INC. | $32.13 | 2019 | |
| Myovant Sciences INC. | $30.45 | 2022 | |
| Acerus Pharmaceuticals Corporation | $29.39 | 2021 | |
| Tolmar, INC. | $27.99 | 2023 | |
| Axonics, INC. | $27.07 | 2023 | Axonics |
| Dendreon Pharmaceuticals LLC | $26.27 | 2019 | |
| Sumitomo Pharma America, INC. | $24.01 | 2023 | Orgovyx |
| Progenics Pharmaceuticals, INC. | $22.64 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.08 | 2023 | |
| Abbott Laboratories | $17.92 | 2023 | Axium |
| Olympus America INC. | $16.53 | 2022 | |
| Merck Sharp & Dohme LLC | $15.28 | 2022 | |
| Travere Therapeutics, INC. | $13.41 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.21 | 2023 | Lynparza |
| Blue Earth Diagnostics | $13.02 | 2019 | |
| Laborie Medical Technologies Corp. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.